Welcome, Guest. Please login or register.
April 26, 2024, 07:49:51 am

Login with username, password and session length


Members
  • Total Members: 6307
  • Latest: golfer
Stats
  • Total Posts: 55126
  • Total Topics: 4851
  • Online Today: 134
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 109
Total: 109

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: AbbVie’s G/P, An All-Genotype Hep C Regimen, Cures Almost All Those With Cirrhos  (Read 5324 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
AbbVie’s investigational all-genotype hepatitis C virus (HCV) treatment glecaprevir/pibrentasvir, known as G/P, cured the virus in almost all those with compensated cirrhosis, the milder form of cirrhosis.

AbbVie applied for FDA approval of G/P in February. A decision is expected in late June.

The Phase III multicenter, open-label EXPEDITION-1 trial gave 12 weeks of G/P to 146 adults with genotypes 1, 2, 4, 5 and 6 and Child-Pugh A cirrhosis, also known as compensated cirrhosis. The trial included those who were being treated for HCV for the first time as well as those who had been treated before with interferon-based treatments.

Read more...
https://www.hepmag.com/article/abbvies-gp-allgenotype-hep-c-regimen-cures-almost-cirrhosis

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.